These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31416721)

  • 1. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management.
    Ahmed KA; Liveringhouse CL; Mills MN; Figura NB; Grass GD; Washington IR; Harris EE; Czerniecki BJ; Blumencranz PW; Eschrich SA; Scott JG; Diaz R; Torres-Roca JF
    EBioMedicine; 2019 Sep; 47():163-169. PubMed ID: 31416721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Scott JG; Berglund A; Schell MJ; Mihaylov I; Fulp WJ; Yue B; Welsh E; Caudell JJ; Ahmed K; Strom TS; Mellon E; Venkat P; Johnstone P; Foekens J; Lee J; Moros E; Dalton WS; Eschrich SA; McLeod H; Harrison LB; Torres-Roca JF
    Lancet Oncol; 2017 Feb; 18(2):202-211. PubMed ID: 27993569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
    Torres-Roca JF; Fulp WJ; Caudell JJ; Servant N; Bollet MA; van de Vijver M; Naghavi AO; Harris EE; Eschrich SA
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):631-8. PubMed ID: 26461005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients.
    Wang SE; Sun YD; Zhao SJ; Wei F; Yang G
    Math Biosci Eng; 2019 Sep; 17(1):92-104. PubMed ID: 31731341
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer.
    Xia H; Li Z; Lin Y; Lin Y; Zeng L; Xu B; Yao Q; Zheng R
    Sci Rep; 2024 Sep; 14(1):21572. PubMed ID: 39284851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
    Scott JG; Sedor G; Ellsworth P; Scarborough JA; Ahmed KA; Oliver DE; Eschrich SA; Kattan MW; Torres-Roca JF
    Lancet Oncol; 2021 Sep; 22(9):1221-1229. PubMed ID: 34363761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
    Chiang CL; Chan KSK; Li H; Ng WT; Chow JCH; Choi HCW; Lam KO; Lee VHF; Ngan RKC; Lee AWM; Eschrich SA; Torres-Roca JF; Wong JWH
    Radiother Oncol; 2024 Jul; 196():110287. PubMed ID: 38636709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
    Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
    JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma.
    Ho E; De Cecco L; Cavalieri S; Sedor G; Hoebers F; Brakenhoff RH; Scheckenbach K; Poli T; Yang K; Scarborough JA; Campbell S; Koyfman S; Eschrich SA; Caudell JJ; Kattan MW; Licitra L; Torres-Roca JF; Scott JG
    medRxiv; 2023 Sep; ():. PubMed ID: 37745365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose.
    Ahmed KA; Scott JG; Arrington JA; Naghavi AO; Grass GD; Perez BA; Caudell JJ; Berglund AE; Welsh EA; Eschrich SA; Dilling TJ; Torres-Roca JF
    J Thorac Oncol; 2018 Aug; 13(8):1121-1127. PubMed ID: 29733909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study.
    Bhoo-Pathy N; Verkooijen HM; Wong FY; Pignol JP; Kwong A; Tan EY; Aishah Taib N; Nei WL; Ho GF; Tan B; Chan P; Lee SC; Hartman M; Yip CH; Dent R
    Int J Cancer; 2015 Nov; 137(10):2504-12. PubMed ID: 26018878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery.
    Fastner G; Hauser-Kronberger C; Moder A; Reitsamer R; Zehentmayr F; Kopp P; Fussl C; Fischer T; Deutschmann H; Sedlmayer F
    Strahlenther Onkol; 2016 Jan; 192(1):1-7. PubMed ID: 26403912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy.
    Yuan Z; Grass GD; Azizi M; Ahmed KA; Yoder GSJ; Welsh EA; Fulp WJ; Dhillon J; Torres-Roca JF; Giuliano AR; Spiess PE; Johnstone PA
    Rep Pract Oncol Radiother; 2019; 24(6):593-599. PubMed ID: 31719799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omission of radiation therapy following breast conservation in older (≥70 years) women with T1-2N0 triple-negative breast cancer.
    Haque W; Verma V; Hsiao KY; Hatch S; Arentz C; Szeja S; Schwartz M; Niravath P; Bonefas E; Miltenburg D; Brian Butler E; Teh BS
    Breast J; 2019 Nov; 25(6):1126-1133. PubMed ID: 31273872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients.
    O'Rorke MA; Murray LJ; Brand JS; Bhoo-Pathy N
    Cancer Treat Rev; 2016 Jun; 47():12-21. PubMed ID: 27214603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.
    Riet FG; Fayard F; Arriagada R; Santos MA; Bourgier C; Ferchiou M; Heymann S; Delaloge S; Mazouni C; Dunant A; Rivera S
    Eur J Cancer; 2017 May; 76():45-51. PubMed ID: 28267657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes.
    Chen L; Zhang J; Chen J; Liu L; Liang L; Shangguan Z; Wang D
    Oncotarget; 2017 Jun; 8(26):42917-42925. PubMed ID: 28476034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy in the locoregional treatment of triple-negative breast cancer.
    Moran MS
    Lancet Oncol; 2015 Mar; 16(3):e113-22. PubMed ID: 25752562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival.
    Kindts I; Buelens P; Laenen A; Van Limbergen E; Janssen H; Wildiers H; Weltens C
    Breast; 2017 Apr; 32():18-25. PubMed ID: 28012411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.